Flexion Therapeutics (FLXN) Stock Price, Quote, News and Overview
NASDAQ:FLXN - Nasdaq -
FLXN Quote, Performance and Key Statistics
9.12
-0.02 (-0.22%)
The current stock price of FLXN is 9.12 null. In the past month the price decreased by -1.94%. In the past year, price decreased by -19.72%.
FLXN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About FLXN
Company Profile
Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. The company is headquartered in Burlington, Massachusetts and currently employs 257 full-time employees. The company went IPO on 2014-02-12. The firm is focused on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), the common form of arthritis. Its product candidate, ZILRETTA, is the intra-articular (IA) injection indicated for the management of OA knee pain. The company is approved by Food and Drug Administration (FDA) to manage osteoarthritis knee pain. The ZILRETTA is a non-opioid therapy that employs its microsphere technology to provide pain relief. The company markets ZILRETTA to prescribing physicians through its own field sales force of Musculoskeletal Business Managers (MBMs). The firm's other product candidates include FX201 and FX301. The FX201 is an IA gene therapy product candidate in clinical development for the treatment of OA. The FX301 is developed as a locally administered peripheral analgesic nerve block for management of post-operative pain.
Company Info
Flexion Therapeutics
10 Mall Rd Ste 301
Burlington MASSACHUSETTS 01803 US
CEO: Michael D. Clayman
Employees: 257
Company Website: https://flexiontherapeutics.com/
Phone: 17813057777.0
Flexion Therapeutics / FLXN FAQ
What is the stock price of Flexion Therapeutics today?
The current stock price of FLXN is 9.12 null. The price decreased by -0.22% in the last trading session.
What is the ticker symbol for Flexion Therapeutics stock?
The exchange symbol of Flexion Therapeutics is FLXN and it is listed on the Nasdaq exchange.
On which exchange is FLXN stock listed?
FLXN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Flexion Therapeutics stock?
15 analysts have analysed FLXN and the average price target is 12.62 null. This implies a price increase of 38.4% is expected in the next year compared to the current price of 9.12. Check the Flexion Therapeutics stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Flexion Therapeutics worth?
Flexion Therapeutics (FLXN) has a market capitalization of 458.42M null. This makes FLXN a Small Cap stock.
How many employees does Flexion Therapeutics have?
Flexion Therapeutics (FLXN) currently has 257 employees.
What are the support and resistance levels for Flexion Therapeutics (FLXN) stock?
Flexion Therapeutics (FLXN) has a support level at 9.11 and a resistance level at 9.45. Check the full technical report for a detailed analysis of FLXN support and resistance levels.
Is Flexion Therapeutics (FLXN) expected to grow?
The Revenue of Flexion Therapeutics (FLXN) is expected to grow by 26.13% in the next year. Check the estimates tab for more information on the FLXN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Flexion Therapeutics (FLXN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FLXN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FLXN, evaluating the profitability, health, valuation and growth aspects
- Flexion Therapeutics (FLXN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Flexion Therapeutics (FLXN) Sales and EPS estimates to see what analysts future expectations are.
- Flexion Therapeutics (FLXN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Flexion Therapeutics (FLXN) Insider and Institutional Ownership to learn about the owners and their transactions.
- Flexion Therapeutics (FLXN) Stock Chart to make your own analysis
- Flexion Therapeutics (FLXN) Latest news and press-releases to stay up to date.
Does Flexion Therapeutics (FLXN) stock pay dividends?
FLXN does not pay a dividend.
When does Flexion Therapeutics (FLXN) report earnings?
Flexion Therapeutics (FLXN) will report earnings on 2022-03-09, after the market close.
What is the Price/Earnings (PE) ratio of Flexion Therapeutics (FLXN)?
Flexion Therapeutics (FLXN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.61).
FLXN Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to FLXN. When comparing the yearly performance of all stocks, FLXN is one of the better performing stocks in the market, outperforming 89.56% of all stocks.
FLXN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FLXN. FLXN has a bad profitability rating. Also its financial health evaluation is rather negative.
FLXN Financial Highlights
Over the last trailing twelve months FLXN reported a non-GAAP Earnings per Share(EPS) of -2.61. The EPS increased by 33.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -100.33% | ||
| ROA | -46.22% | ||
| ROE | N/A | ||
| Debt/Equity | -3.04 |
FLXN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 79% to FLXN. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 18.99% and a revenue growth 26.13% for FLXN